复方苦参注射液联合GP方案化疗治疗晚期非小细胞肺癌47例临床观察

Clinical Efficacy of Compound Matrine Injection in Combination with GP Chemotherapy for Advanced Non-small Cell Lung Cancer

目的:观察复方苦参注射液联合GP方案化疗治疗晚期非小细胞肺癌的安全性及疗效。方法:将47例患者随机分为2组。治疗组24例,采用复方苦参注射液联合GP方案化疗;对照组23例,单纯用GP方案化疗。比较两组近期实体瘤疗效、生活质量改善以及不良反应。结果:近期疗效有效率治疗组为37.5%,对照组为30.4%,两组比较无显著性差异(P>0.05)。治疗组生活质量评分(KPS)好转率为54.2%,对照组为34.8%,两组比较有显著性差异(P<0.05)。治疗组化疗后外周血WBC、Hb、BPC均降低,但对照组下降更为明显(P<0.05)。结论:复方苦参注射液在晚期非小细胞肺癌化疗中有减毒增效、提高生存质量的作用。

OBJECTIVE： To observe the efficacy and safety of Compound Matrine injection in combination with GP chemotherapy in the treatment of advanced non - small cell lung cancer （NSCLC）. METHODS ： A total of 47 patients with advanced NSCLC were enrolled： 24 in the trial group were assigned to receive Compound Matrine injection in combination with GP chemotherapy and 23 in the control group to receive GP chemotherapy alone. The short - term efficacy on solid tumor,： improvement of life quality and the toxicity were compared between the two groups. RESULTS： There were no significant differences between the two groups in short - term response rate （37.5 % in the trial group vs. 30.4 % in the control group） （P 〉 0.05）. However, significant differences were noted between the two groups in the improvement rate of quality of life （54.2% in the trial group vs. 34.8% in control group） （P 〈 0.05）. After undergoing chemotherapy, the reduction in WBC, Hb and BPC in the trial group was less than in the control group （ P 〈 0.05 ）. CONCLUSION： Compound Matrine injection showed proved efficacy of attenuation and synergism while improving quality of life in the treatment of patients with advanced NSCLC.